We reach more than 65,000 registered users in Dec!!

EMA to quickly review Eli Lilly, Incyte arthritis drug for COVID-19 use

The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co's rheumatoid arthritis drug Olumiant for hospitalized COVID-19 patients getting oxygen, the agency said on Thursday, as the search for treatment options continues.

Leave a comment

Search Similar Posts